Michael H. Mulroy - 24 Mar 2022 Form 4 Insider Report for Lineage Cell Therapeutics, Inc. (LCTX)

Role: Director
Signature: /s/ Grant Harbert, as Attorney-in-Fact
Issuer symbol: LCTX
Transactions as of: 24 Mar 2022
Net transactions value: +$9,800
Form type: 4
Filing time: 25 Mar 2022, 16:15:22 UTC
Previous filing: 01 Jul 2021
Next filing: 06 Jul 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	LCTX	Common Shares, no par value	Purchase	$9,800	+7,000	+2.8%	$1.40	258,555	24 Mar 2022	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported is a weighted average. The shares were purchased in multiple transactions at prices ranging from not less than $1.40 to not more than $1.41. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within such range.

Content

The price reported is a weighted average. The shares were purchased in multiple transactions at prices ranging from not less than $1.40 to not more than $1.41. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within such range.